FRIDAY, Dec. 6, 2024 (HealthDay News) — Eating lots of ultra-processed foods appears linked to a buildup of fat in the thighs, which in turn raises a person’s odds for arthritis in the knees, new research shows. “In an adult population at risk for but without knee or hip osteoarthritis,Continue Reading
THURSDAY, Dec. 5, 2024 (HealthDay News) — The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs’ cost should be covered by Medicare, Medicaid and private insurers. Late last month, the Biden administration proposed that the drugs be covered by MedicareContinue Reading
THURSDAY, Dec. 5, 2024 (HealthDay News) — Fatty liver disease may contribute to fragmented sleep patterns, robbing already sick people of good rest, a new study finds. These folks woke up more often in the night, and then lay awake longer waiting for slumber to reclaim them, researchers found. TheseContinue Reading
WEDNESDAY, Dec. 4, 2024 (HealthDay News) — Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. “Given the increased interest around obesity medications, we conducted this study to help health care providers and patients makeContinue Reading
TUESDAY, Dec. 3, 2024 (HealthDay News) — GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell, too. Now, researchers at the Massachusetts Institute of Technology (MIT) say they’ve developedContinue Reading
TUESDAY, Dec. 3, 2024 (HealthDay News) — An accumulation of fat lurking around the organs of obese people is strongly linked to a buildup of Alzheimer’s-linked proteins in the brain, new research finds. Buildup of this visceral fat in middle age may boost levels of the two damaging brain proteins,Continue Reading
WEDNESDAY, Nov. 27, 2024 (HealthDay News) — The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes in obese prediabetic patients by more than 90% during a three-year period compared to placebo, trial resultsContinue Reading
TUESDAY, Nov. 26, 2024 (HealthDay News) — The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration. Right now, a law passed byContinue Reading
TUESDAY, Nov. 26, 2024 (HealthDay News) — The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1sContinue Reading
SATURDAY, Nov. 23, 2024 (HealthDay News) — So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where decadent food will be served in abundance. Luckily, one expert fromContinue Reading
-690x550.jpg)
FRIDAY, Nov. 22, 2024 (HealthDay News) — How long Americans can expect to live varies dramatically — and the gap continues to widen. A new report says health inequalities have, in essence, created 10 Americas. These mutually exclusive populations are divided along familiar fault lines, including race, ethnicity, income andContinue Reading
FRIDAY, Nov. 22, 2024 (HealthDay News) — America’s kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. GLP-1s like Ozempic, Wegovy, Mounjaro and Zepbound all work by making food less desirable, and it’s showing up in more foodContinue Reading
THURSDAY, Nov. 21, 2024 (HealthDay News) — A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows. The test of tirzepatide, brand named Zepbound, included 731 patients with diastolic heart failure and obesity who were followed forContinue Reading
FRIDAY, Nov. 15, 2024 (HealthDay News) — Four out of five men and women in the United States will be overweight or obese by 2050 if current trends hold, a new study warns. About 213 million Americans aged 25 and older will be carrying around excess weight within 25 years,Continue Reading